Biotech, health & vaccines

The Molecular Toolkit

Biotechnology is the engineering of living systems for human ends, and UPSC tests it as applied biology fused with policy. The candidate must command four core technologies.

Recombinant DNA and genetic engineering: the insertion of foreign genes into a host genome, first achieved by Stanley Cohen and Herbert Boyer in 1973. India produces recombinant insulin and recombinant Hepatitis-B vaccine on this principle.

Genome editing with CRISPR-Cas9: discovered as a bacterial immune mechanism and adapted as a programmable molecular scissors by Jennifer Doudna and Emmanuelle Charpentier, who won the 2020 Nobel Prize in Chemistry. In December 2023 the US FDA and UK MHRA approved Casgevy (exa-cel), the first CRISPR therapy, for sickle-cell disease. India's CSIR and the Department of Biotechnology run CRISPR research; the 2024 Nobel-adjacent debate over He Jiankui's 2018 germline-edited babies anchors the ethics question.

Gene therapy and cell therapy: India's first indigenous CAR-T cell therapy, NexCAR19 (developed by IIT Bombay and Tata Memorial Centre, commercialised by ImmunoACT), received CDSCO approval in October 2023 for B-cell cancers, dramatically cheaper than Western equivalents.

GM crops: Bt cotton (containing the Bacillus thuringiensis toxin gene) is the only GM crop commercially cultivated in India, approved in 2002. The Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment cleared GM mustard (DMH-11) in October 2022, a matter now in the Supreme Court.

The Indian Regulatory and Institutional Architecture

Facts examiners reward are institutional. The Department of Biotechnology (DBT), created in 1986 under the Ministry of Science and Technology, is the apex funder; the Biotechnology Industry Research Assistance Council (BIRAC) is its public-sector enterprise for startups. The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), regulates drugs and vaccines under the Drugs and Cosmetics Act, 1940. Clinical trials are governed by the New Drugs and Clinical Trials Rules, 2019.

For genetically modified organisms, the GEAC is the statutory authority under the Environment (Protection) Act, 1986 and the 1989 Rules. The Biotechnology (BioE3) Policy, approved by the Union Cabinet in August 2024, frames Economy, Environment and Employment around bio-manufacturing, climate-resilient agriculture and biofoundries. The National Biopharma Mission (Innovate in India), launched 2017 with World Bank support, scaled vaccine and biologics capacity.

India's biosafety follows a three-tier system: the Institutional Biosafety Committee (IBSC), the Review Committee on Genetic Manipulation (RCGM under DBT), and the GEAC at the top. Candidates should also note the Anusandhan National Research Foundation (ANRF), established by an Act of 2023, which now channels research funding across disciplines including the life sciences.

Vaccine Platforms and India's Pandemic Response

Vaccines are the highest-yield biotech topic because they sit at the intersection of science, manufacturing, diplomacy and public health. The candidate must distinguish the platforms.

Inactivated/whole-virion vaccines use killed pathogen: Covaxin (BBV152), developed by Bharat Biotech with the Indian Council of Medical Research (ICMR) and the National Institute of Virology, Pune, granted emergency use in January 2021. Viral-vector vaccines carry an antigen gene in a harmless adenovirus: Covishield (Oxford-AstraZeneca, manufactured by the Serum Institute of India). mRNA vaccines deliver synthetic messenger RNA in a lipid nanoparticle so host cells make the antigen; Pfizer-BioNTech and Moderna pioneered this, and the 2023 Nobel Prize in Physiology or Medicine went to Katalin Karikó and Drew Weissman for the nucleoside modifications that made it possible. India's Gennova developed GEMCOVAC-19, the country's first indigenous mRNA vaccine, with restricted approval in 2022. Protein-subunit vaccines include Corbevax and the DNA-plasmid platform produced India's ZyCoV-D (Zydus Cadila), the world's first approved DNA vaccine for humans, in August 2021.

India administered over 2.2 billion COVID-19 doses under the CoWIN digital platform. Vaccine Maitri, launched January 2021, supplied doses to over 90 countries, a soft-power instrument GS-2 and GS-3 both exploit.

Public Health Infrastructure and the Exam Frame

The Universal Immunisation Programme (UIP), one of the largest in the world, and Mission Indradhanush (2014) target full immunisation. The National Health Mission, Ayushman Bharat (2018, with Health and Wellness Centres and the PM-JAY insurance arm), and the Ayushman Bharat Digital Mission (2021) form the delivery scaffold. The Indian SARS-CoV-2 Genomics Consortium (INSACOG), set up December 2020, performs genomic surveillance of variants.

Why this matters for the exam

This lesson directly serves Prelims GS (factual: which vaccine uses which platform, which body approves GM crops, what BioE3 stands for) and Mains GS-3 under "developments and applications of science and technology" and "issues relating to intellectual property rights." PYQ patterns are explicit: Prelims 2022 asked about the mode of action of mRNA vaccines; 2021 and 2019 carried CRISPR/gene-editing items; Mains 2021 asked candidates to evaluate India's vaccine development and diplomacy. Examiners reward the candidate who pairs a mechanism (how mRNA or CRISPR works) with an institution (CDSCO, GEAC, DBT) and a dated instance (NexCAR19 approval October 2023, GM mustard clearance October 2022). For Mains answers, always close with a balanced view: biosafety, the TRIPS waiver debate (the WTO MC12 decision of June 2022), equitable access and the precautionary principle. Retain the distinction between a vector and an mRNA platform — it is the single most repeated trap.